lundi 26 février 2018

Onco Actu du 26 février 2018

1. Biologie

How Cells Pack Tangled DNA Into Neat Chromosomes [Wired]

3.1.1 Prévention - Tabac - e-cigs

Nick Hopkinson: Making sense of e-cigarettes—Public Health England’s review of the evidence [BMJ]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA Publishes Final Rule and Guidance on Acceptance of Clinical Data to Support Medical Device Applications and Submissions [FDA Law Blog]

A New Regulatory Threat to Cancer Patients [Wall Street Journal]

5. Traitements

Reducing Overtreatment of Cancer With Precision Medicine [JAMA]

5.10 Traitements - Essais

Precision drug could treat different cancers with rare gene fault [Cancer Research UK]

EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting [British Journal of Cancer]

5.2 Pharma

Merck’s melanoma drug shows early promise for resistant cancers in PhI tria [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

FDA Expands Use of Durvalumab to Non–small Cell Lung Cancer [Cancer Research Catalyst]

5.3.4 Traitements - AMM (FDA, EMA,...)

Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma [Pfizer]

Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer [Puma]

Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe [Amgen]

Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF® [Pfizer]

Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer [AstraZeneca]

Hit by an expected EMA rejection, Puma plans to appeal negative opinion on neratinib [EndPoints]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2018 [EMA]

EU panel recommends against nod for Puma Biotech's breast cancer drug [Reuters]

5.4 Traitements - Economie

Three thyroid cancer drugs approved for NHS in England [Cancer Research UK]

6.1 Observation

Adherence to Follow-up is Low in Adolescent and Young Adult Cancer Survivors [ESMO]

6.10 Politiques

One of the most powerful science policy jobs in Brussels changes hands [Science]

6.10.1 Politiques (USA)

The Trump effect: PwC report says the FDA has slammed the brakes on significant new drug regulations [EndPoints]

A successful cancer researcher confronts a new challenge: getting elected to Congress [Science]